NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the rapid detection and identification of live-cell bacteria and microorganisms, announced today the U.S. Environmental Protection Agency (EPA) intends to expand its Cooperative Research And Development Agreement (CRADA) with NanoLogix to include additional water-borne pathogens. To accommodate the additional research, the company will add two scientists to its staff at its Cincinnati laboratory. More information on the NanoLogix CRADA can be found at the EPA MCEARD News Archive where an article on the company's work can be found two-thirds down the page.
University of Texas Health Science Center - Houston Group B Streptococcus Update
NanoLogix is pleased to announce Phase I of the Group B Strep research utilizing NanoLogix technology is expected to be published by the end of August, 2011 in a major peer-reviewed American medical journal. In addition, lead researcher on the UTHSC-Houston clinical trial, Dr. Jonathan Faro M.D., Ph.D., assistant professor in General Obstetrics & Gynecology at UTHSC-Houston, will present these Phase I findings at the Central Association of Obstetricians and Gynecologists Annual Meeting on October 26-29, 2011. Results of the completed UTHSC Phase II trial are currently being prepared for publication. Meanwhile, the final phase of the 300-patient clinical trial (constituting Phase III of the Group B Strep trial) is on-going and nearing completion.
NanoLogix In the News
Recently, NanoLogix technology has been featured prominently in several media outlets, including:
- Pharmaceutical Manufacturing: Rapid Microbiological Technologies- A Talk With Bret Barnhizer of NanoLogix
- MedCity News: NanoLogix eyes FDA clearance of rapid diagnostic bacteria tests
- Medical Laboratory Observer: NanoLogix' Barnhizer accelerates the rapid detection "revolution"
- Lab Manager Magazine: Bacterial Culturing for Faster Microbe Detection
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients